Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
33
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Merck & Co., Inc. | 10% Owner | 1 | $492.14M | $0 | 2024-03-11 |
| Chin Mark | Director, 10% Owner | 36 | $6.00M | $5.65M | 2024-03-11 |
| Walker Luke Nathaniel | Chief Medical Officer | 7 | $0 | $0 | 2024-03-11 |
| Bucher James B | Chief Legal Officer | 2 | $0 | $0 | 2024-03-11 |
| New Leaf Venture Associates III, L.P. | Director, 10% Owner | 6 | $0 | $0 | 2024-03-11 |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | 7 | $0 | $0 | 2024-03-11 |
| Robbins Andrew R | Director | 9 | $0 | $0 | 2024-03-11 |
| DRACHMAN JONATHAN G | Director | 14 | $0 | $0 | 2024-03-11 |
| EASTLAND JULIA MARIE | President and CEO | 13 | $0 | $0 | 2024-03-11 |
| Myers Scott Dunseth | Director | 15 | $0 | $0 | 2024-03-11 |
| HUNT RONALD | Director, 10% Owner | 46 | $20.00M | $0 | 2024-03-11 |
| SILVERNAIL LAUREN P | Director | 6 | $0 | $0 | 2024-03-11 |
| BAILES JOSEPH S | Director | 11 | $0 | $0 | 2024-03-11 |
| Lathi Vijay K | 10% Owner | 4 | $0 | $0 | 2023-10-25 |
| Viney Joanne L. | Director | 8 | $0 | $0 | 2023-04-01 |
| Colowick Alan | Director | 5 | $0 | $0 | 2023-04-01 |
| Wesche Holger | Chief Scientific Officer | 43 | $0 | $1.14M | 2022-01-28 |
| Sacks Natalie | Chief Medical Officer | 65 | $0 | $1.27M | 2022-01-28 |
| Erbez Georgia | Chief Financial Officer | 13 | $279.0K | $0 | 2022-01-28 |
| MPM Oncology Impact Management LP | 10% Owner | 10 | $0 | $1.96M | 2021-06-02 |
| MPM Oncology Impact Management GP LLC | 10% Owner | 15 | $0 | $9.22M | 2021-05-27 |
| UBS Oncology Impact Fund L.P. | 10% Owner | 6 | $0 | $998.4K | 2021-05-24 |
| Oncology Impact Fund (Cayman) Management L.P. | 10% Owner | 22 | $3.50M | $2.17M | 2021-05-12 |
| GADICKE ANSBERT | 10% Owner | 27 | $7.00M | $9.21M | 2021-05-05 |
| EVNIN LUKE | Other | 36 | $3.50M | $16.08M | 2021-04-15 |
| MPM BioVentures 2014 (B), L.P. | 10% Owner | 4 | $0 | $296.3K | 2021-04-12 |
| MPM Asset Management Investors BV2014 LLC | 10% Owner | 3 | $0 | $1.84M | 2021-02-09 |
| McMahon Gerald PhD | President and CEO | 7 | $31.3K | $0 | 2021-01-28 |
| New Leaf Venture Management III, L.L.C. | 10% Owner | 9 | $10.00M | $0 | 2021-01-11 |
| Arix Bioscience plc | 10% Owner | 10 | $6.00M | $13.12M | 2020-05-28 |
| Baeuerle Patrick | Director | 7 | $0 | $1.40M | 2020-05-28 |
| Arix Bioscience Holdings Ltd | 10% Owner | 3 | $0 | $621.9K | 2019-12-17 |
| MPM BioVentures 2014 GP LLC | 10% Owner | 15 | $3.50M | $21.3K | 2019-02-12 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Bucher James B | Chief Legal Officer | D To issuer deriv | 2024-03-11 | 2024-03-11 | 110,000 | — | $0 | 0 | SEC↗ |
| BAILES JOSEPH S | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,300 | — | $0 | 0 | SEC↗ |
| BAILES JOSEPH S | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 3,142 | — | $0 | 0 | SEC↗ |
| BAILES JOSEPH S | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 1,016 | — | $0 | 0 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | D To issuer deriv | 2024-03-11 | 2024-03-11 | 40,759 | — | $0 | 0 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,765 | — | $0 | 0 | SEC↗ |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | D To issuer deriv | 2024-03-11 | 2024-03-11 | 6,499 | — | $0 | 0 | SEC↗ |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | D To issuer deriv | 2024-03-11 | 2024-03-11 | 8,643 | — | $0 | 0 | SEC↗ |
| Robbins Andrew R | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,300 | — | $0 | 0 | SEC↗ |
| Robbins Andrew R | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 1,016 | — | $0 | 0 | SEC↗ |
| DRACHMAN JONATHAN G | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 5,531 | — | $0 | 0 | SEC↗ |
| DRACHMAN JONATHAN G | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,300 | — | $0 | 0 | SEC↗ |
| DRACHMAN JONATHAN G | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 1,016 | — | $0 | 0 | SEC↗ |
| Chin Mark | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 1,016 | — | $0 | 0 | SEC↗ |
| Chin Mark | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 3,214 | — | $0 | 0 | SEC↗ |
| Chin Mark | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,300 | — | $0 | 0 | SEC↗ |
| Chin Mark | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,033 | — | $0 | 0 | SEC↗ |
| Myers Scott Dunseth | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,033 | — | $0 | 0 | SEC↗ |
| Myers Scott Dunseth | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 4,600 | — | $0 | 0 | SEC↗ |
| Walker Luke Nathaniel | Chief Medical Officer | D To issuer deriv | 2024-03-11 | 2024-03-11 | 30,500 | — | $0 | 0 | SEC↗ |
| Walker Luke Nathaniel | Chief Medical Officer | D To issuer deriv | 2024-03-11 | 2024-03-11 | 10,000 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 1,016 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 299,430 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 686,000 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,300 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 3,214 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,033 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 85,750 | — | $0 | 0 | SEC↗ |
| SILVERNAIL LAUREN P | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,300 | — | $0 | 0 | SEC↗ |
| SILVERNAIL LAUREN P | Director | D To issuer deriv | 2024-03-11 | 2024-03-11 | 2,033 | — | $0 | 0 | SEC↗ |
| New Leaf Venture Associates II | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 85,750 | — | $0 | 0 | SEC↗ |
| New Leaf Venture Associates II | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 686,000 | — | $0 | 0 | SEC↗ |
| New Leaf Venture Associates II | Director, 10% Owner | D To issuer deriv | 2024-03-11 | 2024-03-11 | 299,430 | — | $0 | 0 | SEC↗ |
| Merck & Co., Inc. | 10% Owner | P Buy | 2024-03-11 | 2024-03-11 | 21,397,205 | $23.00 | $492.14M | 1,000 | SEC↗ |
| BAILES JOSEPH S | Director | D To issuer | 2024-03-11 | 2024-03-11 | 5,000 | — | $0 | 0 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | A Award | 2024-03-11 | 2024-03-11 | 31,250 | — | $0 | 269,381 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | D To issuer | 2024-03-11 | 2024-03-11 | 269,381 | — | $0 | 0 | SEC↗ |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | D To issuer | 2024-03-11 | 2024-03-11 | 18,734 | — | $0 | 0 | SEC↗ |
| Robbins Andrew R | Director | D To issuer | 2024-03-11 | 2024-03-11 | 5,000 | — | $0 | 0 | SEC↗ |
| DRACHMAN JONATHAN G | Director | D To issuer | 2024-03-11 | 2024-03-11 | 5,415 | — | $0 | 0 | SEC↗ |
| Chin Mark | Director | D To issuer | 2024-03-11 | 2024-03-11 | 13,224 | — | $0 | 0 | SEC↗ |
| Myers Scott Dunseth | Director | D To issuer | 2024-03-11 | 2024-03-11 | 22,665 | — | $0 | 0 | SEC↗ |
| Walker Luke Nathaniel | Chief Medical Officer | D To issuer | 2024-03-11 | 2024-03-11 | 135,000 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer | 2024-03-11 | 2024-03-11 | 10,000 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer | 2024-03-11 | 2024-03-11 | 395,783 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer | 2024-03-11 | 2024-03-11 | 1,463,386 | — | $0 | 0 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | D To issuer | 2024-03-11 | 2024-03-11 | 13,224 | — | $0 | 0 | SEC↗ |
| SILVERNAIL LAUREN P | Director | D To issuer | 2024-03-11 | 2024-03-11 | 5,000 | — | $0 | 0 | SEC↗ |
| New Leaf Venture Associates II | Director, 10% Owner | D To issuer | 2024-03-11 | 2024-03-11 | 1,463,386 | — | $0 | 0 | SEC↗ |
| New Leaf Venture Associates II | Director, 10% Owner | D To issuer | 2024-03-11 | 2024-03-11 | 395,783 | — | $0 | 0 | SEC↗ |
| New Leaf Venture Associates II | Director, 10% Owner | D To issuer | 2024-03-11 | 2024-03-11 | 10,000 | — | $0 | 0 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award | 2024-03-08 | 2024-03-11 | 415 | — | $0 | 5,415 | SEC↗ |
| Chin Mark | Director | A Award | 2024-03-08 | 2024-03-11 | 424 | — | $0 | 13,224 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award | 2024-03-08 | 2024-03-11 | 424 | — | $0 | 13,224 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | A Award | 2024-01-07 | 2024-01-09 | 178,500 | — | $0 | 232,003 | SEC↗ |
| Walker Luke Nathaniel | Chief Medical Officer | A Award | 2024-01-07 | 2024-01-09 | 115,000 | — | $0 | 135,000 | SEC↗ |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | A Award | 2024-01-07 | 2024-01-09 | 15,000 | — | $0 | 18,362 | SEC↗ |
| Chin Mark | Director | A Award | 2024-01-01 | 2024-01-03 | 1,072 | — | $0 | 12,801 | SEC↗ |
| Myers Scott Dunseth | Director | A Award | 2024-01-01 | 2024-01-03 | 2,048 | — | $0 | 22,666 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award | 2024-01-01 | 2024-01-03 | 1,072 | — | $0 | 12,801 | SEC↗ |
| Bucher James B | Chief Legal Officer | A Award deriv | 2023-12-21 | 2023-12-26 | 110,000 | — | $0 | 110,000 | SEC↗ |
| BAILES JOSEPH S | Director | A Award | 2023-11-27 | 2023-11-28 | 5,000 | — | $0 | 5,000 | SEC↗ |
| Chin Mark | Director | A Award | 2023-11-27 | 2023-11-28 | 5,000 | — | $0 | 11,729 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award | 2023-11-27 | 2023-11-28 | 5,000 | — | $0 | 5,000 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award | 2023-11-27 | 2023-11-28 | 5,000 | — | $0 | 11,729 | SEC↗ |
| Myers Scott Dunseth | Director | A Award | 2023-11-27 | 2023-11-28 | 5,000 | — | $0 | 20,618 | SEC↗ |
| Robbins Andrew R | Director | A Award | 2023-11-27 | 2023-11-28 | 5,000 | — | $0 | 5,000 | SEC↗ |
| SILVERNAIL LAUREN P | Director | A Award | 2023-11-27 | 2023-11-28 | 5,000 | — | $0 | 5,000 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | A Award | 2023-11-26 | 2023-11-28 | 50,000 | — | $0 | 53,503 | SEC↗ |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | A Award | 2023-11-26 | 2023-11-28 | 2,000 | — | $0 | 3,362 | SEC↗ |
| Walker Luke Nathaniel | Chief Medical Officer | A Award | 2023-11-26 | 2023-11-28 | 20,000 | — | $0 | 20,000 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | P Buy deriv | 2023-10-25 | 2023-10-27 | 686,000 | — | $0 | 686,000 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | P Buy deriv | 2023-10-25 | 2023-10-27 | 85,750 | — | $0 | 85,750 | SEC↗ |
| Lathi Vijay K | 10% Owner | P Buy deriv | 2023-10-25 | 2023-10-27 | 85,750 | — | $0 | 85,750 | SEC↗ |
| Lathi Vijay K | 10% Owner | P Buy deriv | 2023-10-25 | 2023-10-27 | 686,000 | — | $0 | 686,000 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | P Buy | 2023-10-25 | 2023-10-27 | 171,500 | — | $0 | 395,783 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | P Buy | 2023-10-25 | 2023-10-27 | 1,372,000 | — | $0 | 1,463,386 | SEC↗ |
| Lathi Vijay K | 10% Owner | P Buy | 2023-10-25 | 2023-10-27 | 171,500 | — | $0 | 395,783 | SEC↗ |
| Lathi Vijay K | 10% Owner | P Buy | 2023-10-25 | 2023-10-27 | 1,372,000 | — | $0 | 1,463,386 | SEC↗ |
| Chin Mark | Director | A Award | 2023-10-01 | 2023-10-02 | 3,035 | — | $0 | 6,729 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award | 2023-10-01 | 2023-10-02 | 3,035 | — | $0 | 6,729 | SEC↗ |
| Myers Scott Dunseth | Director | A Award | 2023-10-01 | 2023-10-02 | 5,797 | — | $0 | 15,618 | SEC↗ |
| Myers Scott Dunseth | Director | A Award | 2023-07-01 | 2023-07-06 | 35,634 | — | $0 | 98,215 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award | 2023-07-01 | 2023-07-06 | 18,656 | — | $0 | 36,941 | SEC↗ |
| Chin Mark | Director | A Award | 2023-07-01 | 2023-07-06 | 18,656 | — | $0 | 36,941 | SEC↗ |
| BAILES JOSEPH S | Director | A Award deriv | 2023-06-22 | 2023-06-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2023-06-22 | 2023-06-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award deriv | 2023-06-22 | 2023-06-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2023-06-22 | 2023-06-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Myers Scott Dunseth | Director | A Award deriv | 2023-06-22 | 2023-06-23 | 46,000 | — | $0 | 46,000 | SEC↗ |
| Robbins Andrew R | Director | A Award deriv | 2023-06-22 | 2023-06-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| SILVERNAIL LAUREN P | Director | A Award deriv | 2023-06-22 | 2023-06-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| Chin Mark | Director | A Award | 2023-04-01 | 2023-04-04 | 18,285 | — | $0 | 18,285 | SEC↗ |
| Colowick Alan | Director | A Award | 2023-04-01 | 2023-04-04 | 16,456 | — | $0 | 16,456 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award | 2023-04-01 | 2023-04-04 | 18,285 | — | $0 | 18,285 | SEC↗ |
| Myers Scott Dunseth | Director | A Award | 2023-04-01 | 2023-04-04 | 34,925 | — | $0 | 62,581 | SEC↗ |
| Viney Joanne L. | Director | A Award | 2023-04-01 | 2023-04-04 | 21,028 | — | $0 | 21,028 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | P Buy deriv | 2023-03-23 | 2023-03-27 | 2,994,305 | — | $0 | 2,994,305 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | P Buy | 2023-03-23 | 2023-03-27 | 10,000 | $1000.00 | $10.00M | 10,000 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | A Award deriv | 2023-01-24 | 2023-01-26 | 407,600 | — | $0 | 407,600 | SEC↗ |
| Walker Luke Nathaniel | Chief Medical Officer | A Award deriv | 2023-01-24 | 2023-01-26 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | A Award deriv | 2023-01-24 | 2023-01-26 | 65,000 | — | $0 | 65,000 | SEC↗ |
| Lanza Frank J | Principal Fin. & Acctng Ofc. | A Award deriv | 2022-11-22 | 2022-11-29 | 86,438 | — | $0 | 86,438 | SEC↗ |
| Walker Luke Nathaniel | Chief Medical Officer | A Award deriv | 2022-10-03 | 2022-10-04 | 305,000 | — | $0 | 305,000 | SEC↗ |
| SILVERNAIL LAUREN P | Director | A Award deriv | 2022-09-15 | 2022-09-19 | 20,335 | — | $0 | 20,335 | SEC↗ |
| BAILES JOSEPH S | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 10,167 | — | $0 | 10,167 | SEC↗ |
| BAILES JOSEPH S | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 31,428 | $1.40 | $44.0K | 31,428 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 32,142 | $1.40 | $45.0K | 32,142 | SEC↗ |
| Colowick Alan | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 28,571 | $1.40 | $40.0K | 28,571 | SEC↗ |
| Colowick Alan | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 10,167 | — | $0 | 10,167 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 10,167 | — | $0 | 10,167 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2022-06-22 | 2022-06-24 | 32,142 | $1.40 | $45.0K | 32,142 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2022-06-22 | 2022-06-24 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Myers Scott Dunseth | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 20,334 | — | $0 | 20,334 | SEC↗ |
| Robbins Andrew R | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Viney Joanne L. | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 37,500 | $1.40 | $52.5K | 37,500 | SEC↗ |
| Viney Joanne L. | Director | A Award deriv | 2022-06-22 | 2022-06-24 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | A Award deriv | 2022-01-28 | 2022-02-01 | 115,000 | — | $0 | 115,000 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | A Award deriv | 2022-01-28 | 2022-02-01 | 155,000 | — | $0 | 155,000 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | A Award deriv | 2022-01-28 | 2022-02-01 | 135,000 | — | $0 | 135,000 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | A Award deriv | 2021-11-11 | 2021-11-15 | 115,000 | — | $0 | 115,000 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | A Award deriv | 2021-11-11 | 2021-11-15 | 155,000 | — | $0 | 155,000 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | A Award deriv | 2021-11-11 | 2021-11-15 | 135,000 | — | $0 | 135,000 | SEC↗ |
| EASTLAND JULIA MARIE | President and CEO | A Award deriv | 2021-11-08 | 2021-11-09 | 350,000 | — | $0 | 350,000 | SEC↗ |
| Myers Scott Dunseth | Director | A Award deriv | 2021-10-25 | 2021-10-26 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | P Buy | 2021-09-22 | 2021-09-22 | 10,300 | $8.10 | $83.4K | 19,215 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2021-07-01 | 2021-07-06 | 10,000 | — | $0 | 21,002 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2021-07-01 | 2021-07-06 | 10,000 | $0.60 | $6.0K | 62,852 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2021-07-01 | 2021-07-06 | 10,000 | $14.00 | $140.0K | 52,852 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-06-02 | 2021-06-02 | 25,118 | $20.50 | $514.9K | 6,328,095 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-06-01 | 2021-06-02 | 18,491 | $20.44 | $378.0K | 6,353,213 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-28 | 2021-06-02 | 100 | $22.60 | $2.3K | 6,371,704 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-28 | 2021-06-02 | 3,100 | $21.92 | $68.0K | 6,371,804 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-28 | 2021-06-02 | 10,685 | $20.88 | $223.1K | 6,374,904 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-27 | 2021-05-27 | 13,961 | $20.26 | $282.8K | 6,385,589 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-26 | 2021-05-27 | 3,198 | $20.04 | $64.1K | 6,399,550 | SEC↗ |
| UBS Oncology Impact Fund L.P. | 10% Owner | S Sale | 2021-05-24 | 2021-05-24 | 5,000 | $20.12 | $100.6K | 6,402,748 | SEC↗ |
| UBS Oncology Impact Fund L.P. | 10% Owner | S Sale | 2021-05-21 | 2021-05-24 | 10,907 | $20.21 | $220.4K | 6,407,748 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-20 | 2021-05-20 | 11,713 | $20.34 | $238.2K | 6,418,655 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-19 | 2021-05-20 | 17,833 | $20.39 | $363.6K | 6,430,368 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-18 | 2021-05-20 | 18,402 | $20.67 | $380.4K | 6,448,201 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-17 | 2021-05-17 | 4,666 | $20.07 | $93.6K | 6,466,603 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-14 | 2021-05-17 | 6,900 | $20.04 | $138.3K | 6,471,269 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-13 | 2021-05-17 | 4,855 | $20.06 | $97.4K | 6,478,169 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-05-12 | 2021-05-12 | 29,684 | $20.53 | $609.4K | 6,483,024 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-05-11 | 2021-05-12 | 7,672 | $21.51 | $165.0K | 6,512,708 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-05-11 | 2021-05-12 | 13,773 | $20.96 | $288.7K | 6,520,380 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-05-10 | 2021-05-12 | 16,722 | $21.78 | $364.2K | 6,534,564 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-05-10 | 2021-05-12 | 411 | $22.46 | $9.2K | 6,534,153 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-05-05 | 2021-05-06 | 59 | $23.09 | $1.4K | 6,551,286 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-05-05 | 2021-05-06 | 10,113 | $22.52 | $227.7K | 6,551,345 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 3,017 | — | $0 | 3,017 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2021-05-04 | 2021-05-07 | 4,807 | — | $0 | 4,807 | SEC↗ |
| EASTLAND JULIA MARIE | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Myers Scott Dunseth | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Robbins Andrew R | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| BAILES JOSEPH S | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Viney Joanne L. | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 2,653 | — | $0 | 2,653 | SEC↗ |
| Viney Joanne L. | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Colowick Alan | Director | A Award deriv | 2021-05-04 | 2021-05-07 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 2,438 | — | $0 | 2,438 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2021-05-04 | 2021-05-14 | 4,658 | — | $0 | 4,658 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| EASTLAND JULIA MARIE | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Myers Scott Dunseth | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Robbins Andrew R | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| BAILES JOSEPH S | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Viney Joanne L. | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Viney Joanne L. | Director | A Award deriv | 2021-05-04 | 2021-05-14 | 2,571 | — | $0 | 2,571 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-04 | 2021-05-04 | 26,230 | $23.03 | $604.1K | 6,564,958 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-04 | 2021-05-04 | 3,500 | $23.33 | $81.7K | 6,561,458 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-03 | 2021-05-04 | 4,401 | $23.45 | $103.2K | 6,591,188 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-05-03 | 2021-05-04 | 26,365 | $23.03 | $607.2K | 6,595,589 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-30 | 2021-05-04 | 268,023 | $22.35 | $5.99M | 6,621,954 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-04-29 | 2021-04-29 | 45,511 | $22.02 | $1.00M | 6,911,758 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-04-29 | 2021-04-29 | 21,781 | $22.54 | $490.9K | 6,889,977 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-04-28 | 2021-04-29 | 14,219 | $21.64 | $307.7K | 6,994,072 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-04-28 | 2021-04-29 | 36,803 | $22.01 | $810.0K | 6,957,269 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-04-27 | 2021-04-29 | 8,328 | $21.26 | $177.1K | 7,008,291 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-04-27 | 2021-04-29 | 3,501 | $20.99 | $73.5K | 7,016,619 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-21 | 2021-04-22 | 555 | $19.48 | $10.8K | 7,020,120 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-21 | 2021-04-22 | 8,417 | $18.94 | $159.4K | 7,020,675 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-04-20 | 2021-04-20 | 834 | $19.09 | $15.9K | 7,029,092 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-04-20 | 2021-04-20 | 21,415 | $18.70 | $400.5K | 7,029,926 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-04-19 | 2021-04-20 | 9,956 | $19.29 | $192.1K | 7,051,441 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-04-19 | 2021-04-20 | 100 | $20.08 | $2.0K | 7,051,341 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-04-16 | 2021-04-20 | 300 | $20.56 | $6.2K | 7,061,397 | SEC↗ |
| Oncology Impact Fund (Cayman) | 10% Owner | S Sale | 2021-04-16 | 2021-04-20 | 5,547 | $19.82 | $109.9K | 7,061,697 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-15 | 2021-04-15 | 8,696 | $20.49 | $178.2K | 7,067,244 | SEC↗ |
| EVNIN LUKE | Other | S Sale | 2021-04-15 | 2021-04-15 | 1,052 | $20.49 | $21.6K | 3,220,844 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-14 | 2021-04-15 | 12,806 | $20.83 | $266.7K | 7,075,940 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-14 | 2021-04-15 | 1,000 | $20.06 | $20.1K | 7,088,746 | SEC↗ |
| EVNIN LUKE | Other | S Sale | 2021-04-14 | 2021-04-15 | 1,550 | $20.83 | $32.3K | 3,221,896 | SEC↗ |
| EVNIN LUKE | Other | S Sale | 2021-04-14 | 2021-04-15 | 121 | $20.06 | $2.4K | 3,223,446 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-13 | 2021-04-15 | 13,692 | $19.35 | $264.9K | 7,092,108 | SEC↗ |
| MPM Oncology Impact Management | 10% Owner | S Sale | 2021-04-13 | 2021-04-15 | 2,362 | $20.08 | $47.4K | 7,089,746 | SEC↗ |
| EVNIN LUKE | Other | S Sale | 2021-04-13 | 2021-04-15 | 286 | $20.08 | $5.7K | 3,223,567 | SEC↗ |
| EVNIN LUKE | Other | S Sale | 2021-04-13 | 2021-04-15 | 1,657 | $19.35 | $32.1K | 3,223,853 | SEC↗ |
| MPM BioVentures 2014 (B), L.P. | 10% Owner | S Sale | 2021-04-12 | 2021-04-13 | 48 | $22.68 | $1.1K | 3,225,510 | SEC↗ |
| MPM BioVentures 2014 (B), L.P. | 10% Owner | S Sale | 2021-04-12 | 2021-04-13 | 1,637 | $20.72 | $33.9K | 3,226,369 | SEC↗ |
| MPM BioVentures 2014 (B), L.P. | 10% Owner | S Sale | 2021-04-12 | 2021-04-13 | 811 | $21.52 | $17.5K | 3,225,558 | SEC↗ |
| UBS Oncology Impact Fund L.P. | 10% Owner | S Sale | 2021-04-12 | 2021-04-13 | 13,528 | $20.72 | $280.3K | 7,112,900 | SEC↗ |
| UBS Oncology Impact Fund L.P. | 10% Owner | S Sale | 2021-04-12 | 2021-04-13 | 6,700 | $21.52 | $144.2K | 7,106,200 | SEC↗ |
| UBS Oncology Impact Fund L.P. | 10% Owner | S Sale | 2021-04-12 | 2021-04-13 | 400 | $22.68 | $9.1K | 7,105,800 | SEC↗ |
| MPM BioVentures 2014 (B), L.P. | 10% Owner | S Sale | 2021-04-09 | 2021-04-13 | 10,300 | $23.67 | $243.8K | 3,228,006 | SEC↗ |
| UBS Oncology Impact Fund L.P. | 10% Owner | S Sale | 2021-04-09 | 2021-04-13 | 10,300 | $23.67 | $243.8K | 7,126,428 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2021-04-01 | 2021-04-05 | 1,534 | — | $0 | 31,002 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2021-04-01 | 2021-04-05 | 8,466 | — | $0 | 2,540 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2021-04-01 | 2021-04-05 | 500 | $21.14 | $10.6K | 52,852 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2021-04-01 | 2021-04-05 | 8,466 | $0.60 | $5.1K | 61,318 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2021-04-01 | 2021-04-05 | 1,534 | $0.60 | $920 | 62,852 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2021-04-01 | 2021-04-05 | 9,500 | $20.41 | $193.9K | 53,352 | SEC↗ |
| Colowick Alan | Director | A Award deriv | 2021-03-24 | 2021-03-26 | 20,335 | — | $0 | 20,335 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | M Exercise deriv | 2021-02-17 | 2021-02-18 | 25,000 | — | $0 | 145,908 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | M Exercise | 2021-02-17 | 2021-02-18 | 25,000 | $2.12 | $53.0K | 72,292 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-02-10 | 2021-02-12 | 183,051 | $20.00 | $3.66M | 3,238,306 | SEC↗ |
| MPM Asset Management Investors | 10% Owner | S Sale | 2021-02-09 | 2021-02-09 | 9,400 | $20.25 | $190.3K | 3,421,357 | SEC↗ |
| MPM Asset Management Investors | 10% Owner | S Sale | 2021-02-08 | 2021-02-09 | 72,128 | $20.04 | $1.45M | 3,430,757 | SEC↗ |
| MPM Asset Management Investors | 10% Owner | S Sale | 2021-02-05 | 2021-02-09 | 10,172 | $20.01 | $203.5K | 3,502,885 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-02-04 | 2021-02-04 | 29,730 | $20.37 | $605.6K | 3,513,057 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-02-03 | 2021-02-04 | 41,922 | $20.21 | $847.2K | 3,542,787 | SEC↗ |
| GADICKE ANSBERT | 10% Owner | S Sale | 2021-02-02 | 2021-02-04 | 48,421 | $20.13 | $974.7K | 3,584,709 | SEC↗ |
| McMahon Gerald PhD | President and CEO | A Award deriv | 2021-01-28 | 2021-01-29 | 181,470 | — | $0 | 181,470 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | A Award deriv | 2021-01-28 | 2021-01-29 | 72,000 | — | $0 | 72,000 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | A Award deriv | 2021-01-28 | 2021-01-29 | 80,000 | — | $0 | 80,000 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | A Award deriv | 2021-01-28 | 2021-01-29 | 52,000 | — | $0 | 52,000 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-27 | 2021-01-27 | 706,825 | $20.00 | $14.14M | 3,633,130 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-26 | 2021-01-27 | 1,363 | $21.08 | $28.7K | 4,339,955 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-25 | 2021-01-27 | 13,006 | $21.23 | $276.1K | 4,341,318 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-22 | 2021-01-22 | 24,695 | $21.72 | $536.4K | 4,354,324 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-21 | 2021-01-22 | 20,979 | $22.11 | $463.8K | 4,384,106 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-21 | 2021-01-22 | 200 | $23.77 | $4.8K | 4,379,019 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-21 | 2021-01-22 | 4,887 | $22.61 | $110.5K | 4,379,219 | SEC↗ |
| EVNIN LUKE | 10% Owner | J Other | 2021-01-20 | 2021-01-22 | 101,646 | — | $0 | 4,405,085 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-20 | 2021-01-22 | 2,000 | $24.71 | $49.4K | 4,506,731 | SEC↗ |
| EVNIN LUKE | 10% Owner | S Sale | 2021-01-20 | 2021-01-22 | 15,694 | $23.95 | $375.9K | 4,508,731 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | P Buy | 2021-01-11 | 2021-08-12 | 235,294 | $17.00 | $4.00M | 913,860 | SEC↗ |
| New Leaf Venture Management II | 10% Owner | P Buy | 2021-01-11 | 2021-08-12 | 235,294 | $17.00 | $4.00M | 913,860 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2021-01-04 | 2021-01-06 | 10,000 | — | $0 | 11,006 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2021-01-04 | 2021-01-06 | 3,549 | $19.39 | $68.8K | 52,852 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2021-01-04 | 2021-01-06 | 3,351 | $18.30 | $61.3K | 56,401 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2021-01-04 | 2021-01-06 | 3,100 | $17.32 | $53.7K | 59,752 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2021-01-04 | 2021-01-06 | 10,000 | $0.60 | $6.0K | 62,852 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2020-10-01 | 2020-10-05 | 10,000 | — | $0 | 21,006 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-10-01 | 2020-10-05 | 1,000 | $17.03 | $17.0K | 52,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-10-01 | 2020-10-05 | 9,000 | $16.19 | $145.7K | 53,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2020-10-01 | 2020-10-05 | 10,000 | $0.60 | $6.0K | 62,669 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | P Buy | 2020-08-19 | 2020-08-20 | 5,000 | $11.40 | $57.0K | 8,915 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | P Buy | 2020-08-18 | 2020-08-20 | 2,098 | $11.60 | $24.3K | 3,915 | SEC↗ |
| Erbez Georgia | Chief Financial Officer | P Buy | 2020-07-31 | 2020-08-04 | 1,817 | $10.92 | $19.8K | 1,817 | SEC↗ |
| Viney Joanne L. | Director | A Award deriv | 2020-07-01 | 2020-07-02 | 20,335 | — | $0 | 20,335 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2020-07-01 | 2020-07-02 | 10,000 | — | $0 | 31,006 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-07-01 | 2020-07-02 | 10,000 | $16.20 | $162.0K | 52,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2020-07-01 | 2020-07-02 | 10,000 | $0.60 | $6.0K | 62,669 | SEC↗ |
| EVNIN LUKE | Director, 10% Owner | A Award deriv | 2020-05-28 | 2020-06-01 | 3,587 | — | $0 | 3,587 | SEC↗ |
| EVNIN LUKE | Director, 10% Owner | A Award deriv | 2020-05-28 | 2020-06-01 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Baeuerle Patrick | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Baeuerle Patrick | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 2,584 | — | $0 | 2,584 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 3,017 | — | $0 | 3,017 | SEC↗ |
| Chin Mark | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 10,167 | — | $0 | 10,167 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 10,167 | — | $0 | 10,167 | SEC↗ |
| DRACHMAN JONATHAN G | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 2,880 | — | $0 | 2,880 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2020-05-28 | 2020-06-01 | 4,906 | — | $0 | 4,906 | SEC↗ |
| HUNT RONALD | Director, 10% Owner | A Award deriv | 2020-05-28 | 2020-06-01 | 10,167 | — | $0 | 10,167 | SEC↗ |
| EASTLAND JULIA MARIE | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Myers Scott Dunseth | Director | A Award deriv | 2020-05-28 | 2020-06-01 | 10,167 | — | $0 | 10,167 | SEC↗ |
| Arix Bioscience plc | 10% Owner | S Sale | 2020-05-28 | 2020-05-29 | 366,591 | $21.33 | $7.82M | 2,193,704 | SEC↗ |
| Arix Bioscience plc | 10% Owner | S Sale | 2020-05-27 | 2020-05-29 | 12,064 | $22.39 | $270.1K | 2,560,295 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | M Exercise deriv | 2020-05-18 | 2020-05-20 | 1,522 | — | $0 | 45,625 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | S Sale | 2020-05-18 | 2020-05-20 | 1,522 | $14.77 | $22.5K | 45,754 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | M Exercise | 2020-05-18 | 2020-05-20 | 1,522 | $2.12 | $3.2K | 47,276 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2020-05-12 | 2020-05-13 | 1,400 | — | $0 | 41,006 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2020-05-12 | 2020-05-13 | 1,400 | $0.60 | $840 | 54,069 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-05-12 | 2020-05-13 | 1,400 | $14.09 | $19.7K | 52,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2020-05-11 | 2020-05-11 | 1,000 | — | $0 | 42,406 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2020-05-11 | 2020-05-11 | 1,000 | $0.60 | $600 | 53,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-05-11 | 2020-05-11 | 1,000 | $14.07 | $14.1K | 52,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2020-05-08 | 2020-05-11 | 1,000 | — | $0 | 43,406 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-05-08 | 2020-05-11 | 1,000 | $14.00 | $14.0K | 52,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2020-05-08 | 2020-05-11 | 1,000 | $0.60 | $600 | 53,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2020-05-07 | 2020-05-11 | 5,350 | — | $0 | 44,406 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2020-05-07 | 2020-05-11 | 5,350 | $0.60 | $3.2K | 58,019 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-05-07 | 2020-05-11 | 5,350 | $14.13 | $75.6K | 52,669 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | M Exercise deriv | 2020-05-01 | 2020-05-05 | 5,826 | — | $0 | 168,926 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | S Sale | 2020-05-01 | 2020-05-05 | 5,826 | $12.07 | $70.3K | 45,754 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | M Exercise | 2020-05-01 | 2020-05-05 | 5,826 | $2.12 | $12.4K | 51,580 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise deriv | 2020-04-28 | 2020-04-30 | 1,250 | — | $0 | 49,756 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | S Sale | 2020-04-28 | 2020-04-30 | 1,250 | $14.05 | $17.6K | 52,669 | SEC↗ |
| Wesche Holger | Chief Scientific Officer | M Exercise | 2020-04-28 | 2020-04-30 | 1,250 | $0.60 | $750 | 53,919 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | M Exercise deriv | 2020-04-17 | 2020-04-17 | 1,021 | — | $0 | 47,147 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | S Sale | 2020-04-17 | 2020-04-17 | 1,021 | $12.08 | $12.3K | 45,754 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | M Exercise | 2020-04-17 | 2020-04-17 | 1,021 | $2.12 | $2.2K | 46,775 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | M Exercise deriv | 2020-04-16 | 2020-04-17 | 500 | — | $0 | 48,168 | SEC↗ |
| Sacks Natalie | Chief Medical Officer | S Sale | 2020-04-16 | 2020-04-17 | 500 | $12.00 | $6.0K | 45,754 | SEC↗ |